Database Query Results : , , HO-1

HO-1, HMOX1: Click to Expand ⟱
Source:
Type:
(Also known as Hsp32 and HMOX1)
HO-1 is the common abbreviation for the protein (heme oxygenase‑1) produced by the HMOX1 gene.
HO-1 is an enzyme that plays a crucial role in various cellular processes, including the breakdown of heme, a toxic molecule. Research has shown that HO-1 is involved in the development and progression of cancer.
-widely regarded as having antioxidant and cytoprotective effects
-The overall activity of HO‑1 helps to reduce the pro‐oxidant load (by degrading free heme, a pro‑oxidant) and to generate molecules (like bilirubin) that can protect cells from oxidative damage

Studies have found that HO-1 is overexpressed in various types of cancer, including lung, breast, colon, and prostate cancer. The overexpression of HO-1 in cancer cells can contribute to their survival and proliferation by:
  Reducing oxidative stress and inflammation
  Promoting angiogenesis (the formation of new blood vessels)
  Inhibiting apoptosis (programmed cell death)
  Enhancing cell migration and invasion
When HO-1 is at a normal level, it mainly exerts an antioxidant effect, and when it is excessively elevated, it causes an accumulation of iron ions.

A proper cellular level of HMOX1 plays an antioxidative function to protect cells from ROS toxicity. However, its overexpression has pro-oxidant effects to induce ferroptosis of cells, which is dependent on intracellular iron accumulation and increased ROS content upon excessive activation of HMOX1.

-Curcumin   Activates the Nrf2 pathway leading to HO‑1 induction; known for its anti‑inflammatory and antioxidant effects.
-Resveratrol  Induces HO‑1 via activation of SIRT1/Nrf2 signaling; exhibits antioxidant and cardioprotective properties.
-Quercetin   Activates Nrf2 and related antioxidant pathways; contributes to anti‑oxidative and anti‑inflammatory responses.
-EGCG     Promotes HO‑1 expression through activation of the Nrf2/ARE pathway; also exhibits anti‑inflammatory and anticancer properties.
-Sulforaphane One of the most potent natural HO‑1 inducers; triggers Nrf2 nuclear translocation and upregulates a battery of phase II detoxifying enzymes.
-Luteolin    Induces HO‑1 via Nrf2 activation; may also exert anti‑inflammatory and neuroprotective effects in various cell models.
-Apigenin   Has been reported to induce HO‑1 expression partly via the MAPK and Nrf2 pathways; also known for anti‑inflammatory and anticancer activities.
Scientific Papers found: Click to Expand⟱
256- AL,  doxoR,    Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
NRF2↓, HO-1↓, p‑Akt↓,
1235- ALA,  Cisplatin,    α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway
- in-vitro, Nor, HEI-OC1 - ex-vivo, NA, NA
ROS↑, HO-1↓, *toxicity↓, chemoP↑, *ROS↓, *HO-1↑, *SOD1↑, *NRF2↑,
2296- Ba,    The most recent progress of baicalein in its anti-neoplastic effects and mechanisms
- Review, Var, NA
CDK1↓, Cyc↓, p27↑, P21↑, P53↑, TumCCA↑, TumCI↓, MMP2↓, MMP9↓, E-cadherin↑, N-cadherin↓, Vim↓, LC3A↑, p62↓, p‑mTOR↓, PD-L1↓, CAFs/TAFs↓, VEGF↓, ROCK1↓, Bcl-2↓, Bcl-xL↓, BAX↑, ROS↑, cl‑PARP↑, Casp3↑, Casp9↑, PTEN↑, MMP↓, Cyt‑c↑, Ca+2↑, PERK↑, IRE1↑, CHOP↑, Copper↑, Snail↓, Vim↓, Twist↓, GSH↓, NRF2↓, HO-1↓, GPx4↓, XIAP↓, survivin↓, DR5↑,
1390- BBR,  Rad,    Berberine Inhibited Radioresistant Effects and Enhanced Anti-Tumor Effects in the Irradiated-Human Prostate Cancer Cells
- in-vitro, Pca, PC3
RadioS↑, Apoptosis↑, ROS↑, eff↑, BAX↑, Casp3↑, P53↑, p38↑, JNK↑, Bcl-2↓, ERK↓, HO-1↓,
1392- BBR,    Based on network pharmacology and experimental validation, berberine can inhibit the progression of gastric cancer by modulating oxidative stress
- in-vitro, GC, AGS - in-vitro, GC, MKN45
TumCG↓, TumCMig↓, ROS↑, MDA↑, SOD↓, NRF2↓, HO-1↓, Hif1a↓, EMT↓, Snail↓, Vim↓,
2756- BetA,    Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway
- in-vitro, HCC, HUH7 - in-vitro, HCC, H1299
TumCP↓, ROS↓, antiOx↓, TumCG↓, TumCMig↓, NRF2↓, GPx4↓, HO-1↓, NCOA4↑, FTH1↓, Ferritin↑, Ferroptosis↑, GSH↓, MDA↓,
2591- CHr,  doxoR,    Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway
- in-vitro, HCC, Bel-7402
NRF2↓, ChemoSen↑, HO-1↓,
2590- CHr,    Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway
- in-vitro, GBM, T98G - in-vitro, GBM, U251 - in-vitro, GBM, U87MG
TumCP↓, TumCMig↓, TumCI↓, NRF2↓, HO-1↓, NADPH↓, ERK↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1↓, hTERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
1410- CUR,    Curcumin induces ferroptosis and apoptosis in osteosarcoma cells by regulating Nrf2/GPX4 signaling pathway
- vitro+vivo, OS, MG63
tumCV↓, Apoptosis↑, TumCG↓, NRF2↓, GPx4↓, HO-1↓, xCT↓, ROS↑, MDA↑, GSH↓,
1847- dietFMD,  VitC,    Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers
- in-vitro, PC, PANC1
TumCG↓, ChemoSen↑, eff↑, HO-1↓, Ferritin↓, Iron↑, ROS↑, TumCD↑, IGF-1↓, eff↓, eff↓,
1846- dietFMD,  VitC,    A fasting-mimicking diet and vitamin C: turning anti-aging strategies against cancer
- Study, Var, NA
TumCG↓, ChemoSen↑, ChemoSideEff↓, ROS↑, Fenton↑, H2O2↑, eff↑, HO-1↓, DNAdam↑, eff↑,
1859- dietFMD,  Chemo,    Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity
- in-vitro, BC, 4T1 - in-vivo, Melanoma, B16-BL6
CLP↑, CD8+↑, TumCG↓, HO-1↓, TILs↑,
1863- dietFMD,  Chemo,    Effect of fasting on cancer: A narrative review of scientific evidence
- Review, Var, NA
eff↑, ChemoSideEff↓, ChemoSen↑, Insulin↓, HDAC↓, IGF-1↓, STAT5↓, BG↓, MAPK↓, HO-1↓, ATG3↑, Beclin-1↑, p62↑, SIRT1↑, LAMP2↑, OXPHOS↑, ROS↑, P53↑, DNAdam↑, TumCD↑, ATP↑, Treg lymp↓, M2 MC↓, CD8+↑, Glycolysis↓, GutMicro↑, GutMicro↑, Warburg↓, Dose↝,
1626- dietSTF,  dietFMD,    When less may be more: calorie restriction and response to cancer therapy
- Review, Var, NA
CRM↑, ChemoSen↑, RadioS↑, eff↑, eff↑, IGF-1↓, TumCG↓, AMPK↑, eff↑, ChemoSen↑, RadioS↑, ROS↑, DNAdam↑, eff↑, HO-1↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumMeta↓, TumCI↓, TumAuto↑, VEGFR2↓, MAPK↓, PI3K↓, Akt↓, PD-1↓, NOTCH↓, PCNA↓, Ki-67↓, cycD1↓, CDK2↑, CDK6↓, Bcl-2↓, cl‑PARP↑, BAX↑, Casp3↑, DR4↑, DR5↑, Snail↓, MMP2↓, MMP9↓, TGF-β↑, PKCδ↓, β-catenin/ZEB1↓, SIRT1↓, HO-1↓, ROS↑, CHOP↑, Cyt‑c↑, MMP↓, OCR↓, AMPK↑, Hif1a↓, NF-kB↓, E-cadherin↑, Vim↓, EMT↓, LC3II↑, CIP2A↓, GLUT1↓, PDH↝, MAD↓, LDH↓, GSTs↑, NOTCH↓, survivin↓, XIAP↓, ER Stress↑, ChemoSideEff↓, ChemoSen↑,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
*BioAv↓, antiOx↓, Inflam↓, TumCP↓, TumCCA↑, cycD1↓, cycE↓, P53↑, P21↑, COX2↓, NF-kB↓, Akt↑, NOTCH↓, CDK2↓, CDK6↓, JAK↓, STAT3↓, EGFR↓, p‑ERK↓, p‑Akt↓, p‑STAT3↓, TGF-β↓, SMAD3↓, CDK6↓, Wnt/(β-catenin)↓, Myc↓, survivin↓, CDK8↓, PKCδ↓, tumCV↓, RadioS↑, eff↑, MDM2↓, XIAP↓, p‑RB1↓, PTEN↑, p‑FAK↓, Bax:Bcl2↑, Bcl-xL↓, Mcl-1↓, PUMA↑, NOXA↑, MMP↓, Cyt‑c↑, ROS↑, Ca+2↝, Endoglin↑, Diablo↑, AIF↑, iNOS↓, Casp9↑, Casp3↑, cl‑PARP↑, RadioS↑, Hif1a↓, HO-1↓, HO-2↓, SIRT1↓, selectivity↑, Dose∅, NHE1↓, Glycolysis↓, GlucoseCon↓, lactateProd↓, PDK1?, PDK1?, ECAR↝, COX1↓, Snail↓, Twist↓, cMyc↓, Telomerase↓, angioG↓, MMP2↓, MMP9↓, VEGF↓, Dose↝, PD-L1↓, eff↑, SIRT6↑, DNAdam↓,
3214- EGCG,    EGCG-induced selective death of cancer cells through autophagy-dependent regulation of the p62-mediated antioxidant survival pathway
- in-vitro, Nor, MRC-5 - in-vitro, Cerv, HeLa - in-vitro, Nor, HEK293 - in-vitro, BC, MDA-MB-231 - in-vitro, CRC, HCT116
mTOR↓, AMPK↑, selectivity↑, ROS↑, selectivity↑, HO-1↓, *NRF2↑, NRF2↓, *HO-1↑,
2514- H2,    Hydrogen: A Novel Option in Human Disease Treatment
- Review, NA, NA
*Inflam↓, *IL1β↓, *IL6↓, *IL8↓, *IL10↓, *TNF-α↓, *ROS↓, *HO-1↓, *NRF2↑, *ER Stress↓, H2O2↑,
1633- HCA,    Hydroxycitric Acid Alleviated Lung Ischemia-Reperfusion Injury by Inhibiting Oxidative Stress and Ferroptosis through the Hif-1α Pathway
- in-vivo, NA, NA - in-vitro, Nor, HUVECs
*other↓, *Inflam↓, *MDA↓, *ROS↓, *Iron↓, *SOD↓, *Hif1a↓, *HO-1↓,
2894- HNK,    Pharmacological features, health benefits and clinical implications of honokiol
- Review, Var, NA - Review, AD, NA
*BioAv↓, *neuroP↑, *BBB↑, *ROS↓, *Keap1↑, *NRF2↑, *Casp3↓, *SIRT3↑, *Rho↓, *ERK↓, *NF-kB↓, angioG↓, RAS↓, PI3K↓, Akt↓, mTOR↓, *memory↑, *Aβ↓, *PPARγ↑, *PGC-1α↑, NF-kB↓, Hif1a↓, VEGF↓, HO-1↓, Foxm1↓, p27↑, P21↑, CDK2↓, CDK4↓, CDK6↓, cycD1↓, Twist↓, MMP2↓, Rho↑, ROCK1↑, TumCMig↓, cFLIP↓, BMPs↑, OCR↑, ECAR↓, *AntiAg↑, *cardioP↑, *antiOx↑, *ROS↓, P-gp↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2927- LT,    Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells
- in-vitro, Cerv, HeLa
TumCMig↓, DNMTs↓, HDAC↓, HATs↓, ac‑H3↓, ac‑H4↓, MMP2↓, MMP9↓, HO-1↓, E-cadherin↑, EZH2↓, HER2/EBBR2↓, IL18↓, IL8↓, IL2↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1↓, CycB↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2589- LT,  Chemo,    Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway
- in-vitro, BC, MDA-MB-231
NRF2↓, HO-1↓, ChemoSen↑, CSCs↓, SIRT1↓,
2588- LT,  Chemo,    Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway
- in-vitro, CRC, HCT116
NRF2↓, NQO1↓, HO-1↓, GSH↓, ChemoSen↑,
2587- LT,    Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs
- in-vitro, Lung, A549
NRF2↓, GSH↓, ChemoSen↑, HO-1↓,
1204- MET,    Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
MDA↑, ROS↑, Iron↑, GSH↓, T-SOD↓, Catalase↓, GPx4↓, xCT↓, NRF2↓, HO-1↓,
1770- PG,    Propyl gallate sensitizes human lung cancer cells to cisplatin-induced apoptosis by targeting heme oxygenase-1 for TRC8-mediated degradation
- in-vitro, Lung, NA
antiOx↑, Inflam↓, HO-1↓, eff↑, ChemoSen↑,
3077- RES,    Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways
- in-vitro, Chon, HTB94
MMP2↓, MMP9↓, SOX9↑, MMPs↓, p‑p38↑, p‑JNK↓, NF-kB↓, HO-1↓,
2132- TQ,    Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis
- in-vivo, Nor, NA
*Weight∅, *antiOx↑, *lipid-P↓, *MMP7↓, *Casp3↓, *BAX↓, *TGF-β↓, *Diff↑, *NRF2↓, *HO-1↓, *NF-kB↓, *IκB↑,
3108- VitC,  QC,    The role of quercetin and vitamin C in Nrf2-dependent oxidative stress production in breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, Lung, A549
NRF2↓, HO-1↓, ROS↑, NRF2⇅,
2275- VitK2,    Delivery of the reduced form of vitamin K2(20) to NIH/3T3 cells partially protects against rotenone induced cell death
- in-vitro, Nor, NIH-3T3
*MMP↓, *ROS↓, *HO-1↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 33

Results for Effect on Cancer/Diseased Cells:
AEG1↓,1,   AIF↑,2,   Akt↓,4,   Akt↑,1,   p‑Akt↓,3,   ALAT↓,1,   ALP↓,1,   AMPK↑,3,   angioG↓,4,   AntiCan↑,1,   antiOx↓,2,   antiOx↑,1,   Apoptosis↑,3,   AR↓,2,   ASC↓,1,   ATG3↑,1,   ATP↑,1,   AXL↓,1,   BAX↑,4,   Bax:Bcl2↑,1,   Bcl-2↓,4,   Bcl-xL↓,3,   Beclin-1↑,1,   BG↓,1,   BioAv↑,2,   BMPs↑,1,   Ca+2↑,3,   Ca+2↝,1,   cachexia↓,1,   CAFs/TAFs↓,1,   cardioP↑,1,   Casp1↓,1,   Casp3↑,6,   cl‑Casp3↑,1,   Casp8↑,1,   cl‑Casp8↑,1,   Casp9↑,2,   cl‑Casp9↑,1,   Catalase↓,2,   CD34↓,1,   CD8+↑,2,   CDC2↓,1,   Cdc42↓,1,   CDK1↓,1,   CDK2↓,3,   CDK2↑,1,   CDK4↓,1,   CDK6↓,4,   CDK8↓,1,   CEA↓,1,   cFLIP↓,1,   cFos↑,1,   chemoP↑,2,   ChemoSen↓,1,   ChemoSen↑,13,   ChemoSideEff↓,3,   CHOP↑,3,   CIP2A↓,1,   CLDN1↓,2,   CLP↑,1,   cMyc↓,1,   p‑cMyc↑,1,   Copper↑,1,   COX1↓,1,   COX2↓,2,   COX2↑,1,   CRM↑,1,   CSCs↓,1,   CXCR4↓,1,   Cyc↓,1,   CycB↓,1,   cycD1↓,5,   cycE↓,1,   CYP1A1↓,1,   Cyt‑c↑,5,   Diablo↑,1,   DNAdam↓,1,   DNAdam↑,5,   DNMTs↓,1,   Dose↝,2,   Dose∅,1,   DR4↑,1,   DR5↑,4,   E-cadherin↓,1,   E-cadherin↑,5,   ECAR↓,1,   ECAR↝,1,   eff↓,2,   eff↑,14,   EGFR↓,2,   EGFR↑,1,   p‑eIF2α↑,2,   EMT↓,5,   Endoglin↑,1,   ER Stress↑,3,   ERK↓,4,   p‑ERK↓,1,   EZH2↓,1,   FAK↓,1,   p‑FAK↓,1,   Fas↑,1,   FasL↑,1,   Fenton↑,1,   Ferritin↓,1,   Ferritin↑,1,   Ferroptosis↑,1,   Fibronectin↓,1,   Foxm1↓,1,   FTH1↓,1,   GlucoseCon↓,1,   GLUT1↓,1,   Glycolysis↓,2,   GPx↓,1,   GPx4↓,4,   GRP78/BiP↑,1,   GSH↓,8,   p‑GSK‐3β↓,1,   GSR↓,1,   GSTs↓,1,   GSTs↑,1,   GutMicro↑,2,   H2O2↑,2,   H3↓,1,   ac‑H3↓,1,   H4↓,1,   ac‑H4↓,1,   HATs↓,1,   HDAC↓,4,   HER2/EBBR2↓,1,   HGF/c-Met↓,1,   Hif1a↓,5,   HK2↓,1,   HO-1↓,29,   HO-2↓,1,   hTERT↓,2,   ICAM-1↓,1,   IFN-γ↓,1,   IGF-1↓,3,   IKKα↓,1,   IL10↓,1,   IL18↓,1,   IL1β↓,1,   IL2↓,1,   IL2↑,1,   IL6↓,2,   IL8↓,1,   Inflam↓,2,   iNOS↓,3,   Insulin↓,1,   IRE1↑,1,   Iron↑,2,   ITGB1↓,1,   JAK↓,1,   JNK↑,2,   p‑JNK↓,1,   p‑JNK↑,1,   Ki-67↓,1,   lactateProd↓,1,   LAMP2↑,1,   LC3A↑,1,   LC3B-II↑,1,   LC3II↑,2,   LDH↓,2,   LDL↓,1,   lipid-P↑,1,   M2 MC↓,1,   MAD↓,1,   MAPK↓,3,   Mcl-1↓,2,   MDA↓,1,   MDA↑,3,   MDM2↓,2,   p‑MDM2↓,1,   MDR1↓,1,   MET↓,1,   p‑MET↓,1,   MMP↓,3,   MMP↑,1,   MMP-10↓,1,   MMP2↓,9,   MMP9↓,7,   MMPs↓,1,   mTOR↓,4,   p‑mTOR↓,1,   Myc↓,1,   N-cadherin↓,3,   NADPH↓,1,   NCOA4↑,1,   neuroP↑,1,   NF-kB↓,6,   p‑NF-kB↑,1,   NHE1↓,1,   NICD↓,1,   NLRP3↓,1,   NOTCH↓,3,   NOTCH1↓,2,   NOTCH1↑,1,   NOXA↑,1,   NQO1↓,2,   NRF2↓,16,   NRF2↑,1,   NRF2⇅,1,   NSE↓,1,   OCR↓,1,   OCR↑,1,   OXPHOS↑,1,   P-gp↓,1,   P21↑,4,   p27↑,2,   p38↑,1,   p‑p38↑,2,   P53↑,5,   p62↓,1,   p62↑,1,   p‑p65↓,1,   PARP↑,2,   cl‑PARP↑,4,   PCNA↓,2,   PD-1↓,2,   PD-L1↓,2,   PDH↝,1,   PDK1?,2,   PDK1↓,1,   PERK↑,1,   PGE2↓,1,   PI3K↓,3,   p‑PI3K↓,1,   PKCδ↓,2,   PPARα↓,1,   PTEN↓,1,   PTEN↑,2,   PUMA↑,1,   Rac1↓,1,   RadioS↑,7,   RAS↓,2,   p‑RB1↓,1,   RenoP↑,1,   Rho↓,1,   Rho↑,1,   ROCK1↓,1,   ROCK1↑,1,   ROS↓,1,   ROS↑,17,   selectivity↑,3,   SIRT1↓,4,   SIRT1↑,1,   SIRT6↑,1,   Slug↓,1,   SMAD3↓,1,   Snail↓,6,   SOD↓,2,   SOD2↓,1,   SOX9↑,1,   p‑Src↓,1,   STAT3↓,3,   p‑STAT3↓,1,   STAT5↓,1,   p‑STAT6↓,1,   survivin↓,4,   T-SOD↓,1,   TAZ↓,1,   Telomerase↓,2,   TET1↑,1,   TGF-β↓,1,   TGF-β↑,1,   TILs↑,1,   TIMP1↑,1,   TIMP2↑,1,   TLR4↓,1,   TNF-α↓,1,   TOP1↓,1,   Treg lymp↓,1,   TumAuto↑,2,   TumCCA↑,2,   TumCD↑,2,   TumCG↓,7,   TumCI↓,3,   TumCMig↓,5,   TumCP↓,5,   tumCV↓,2,   TumMeta↓,1,   Twist↓,4,   Tyro3↓,1,   UPR↑,1,   VEGF↓,6,   VEGFR2↓,2,   Vim↓,5,   Vim↑,1,   VitC↓,1,   VitE↓,1,   Warburg↓,1,   Wnt↓,1,   Wnt/(β-catenin)↓,1,   XBP-1↓,1,   xCT↓,2,   XIAP↓,5,   YAP/TEAD↓,1,   ZO-1↑,1,   β-catenin/ZEB1↓,2,  
Total Targets: 299

Results for Effect on Normal Cells:
AntiAg↑,1,   antiOx↑,3,   AST↓,1,   Aβ↓,1,   BAX↓,1,   BBB↑,1,   BioAv↓,3,   BioAv↑,1,   cardioP↑,1,   Casp3↓,3,   Catalase↑,1,   COX2↓,1,   Diff↑,1,   eff↑,1,   ER Stress↓,1,   ERK↓,1,   GPx↑,1,   GSH↑,1,   GSTs↑,1,   Half-Life↝,1,   Hif1a↓,1,   HO-1↓,4,   HO-1↑,2,   IL10↓,1,   IL10↑,1,   IL1β↓,2,   IL6↓,1,   IL8↓,1,   Inflam↓,2,   iNOS↓,1,   Iron↓,1,   IronCh↑,1,   IκB↑,1,   Keap1↑,1,   lipid-P↓,2,   MDA↓,1,   memory↑,1,   MMP↓,1,   MMP7↓,1,   neuroP↑,1,   NF-kB↓,3,   NRF2↓,1,   NRF2↑,4,   other↓,1,   PGC-1α↑,1,   PPARγ↑,1,   Rho↓,1,   ROS↓,6,   SIRT3↑,1,   SOD↓,1,   SOD↑,1,   SOD1↑,1,   TGF-β↓,1,   TNF-α↓,2,   toxicity↓,2,   Weight∅,1,  
Total Targets: 56

Scientific Paper Hit Count for: HO-1, HMOX1
6 Luteolin
5 diet FMD Fasting Mimicking Diet
4 Chemotherapy
3 Chrysin
3 Vitamin C (Ascorbic Acid)
2 doxorubicin
2 Berberine
2 Ellagic acid
1 Allicin (mainly Garlic)
1 Alpha-Lipoic-Acid
1 Cisplatin
1 Baicalein
1 Radiotherapy/Radiation
1 Betulinic acid
1 Curcumin
1 diet Short Term Fasting
1 EGCG (Epigallocatechin Gallate)
1 Hydrogen Gas
1 HydroxyCitric Acid
1 Honokiol
1 Metformin
1 Propyl gallate
1 Resveratrol
1 Thymoquinone
1 Quercetin
1 Vitamin K2
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:597  State#:0  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page